Nanotechnology and Advanced Materials for Drug Delivery: Engineering, Legal, Educational, and Commercial Implications

Abstract

Nanotechnology and new materials have changed drug delivery because they offer the possibility of targeted controlled and efficient therapeutic concentrations. The analysis discusses the engineering, legal, educational, and commercial implications of nanomedicine informed by literature review, regulatory analysis, educational curriculum, and market trends data. Discussion For the drug loading efficiencies of 50-90% and a particle size of 5-200nm, our engineering analysis predicted that the liposomes, polymeric particles, dendrimers and gold particles could easily be used to target and induce release time periods in such a way the release time would occur at a range of between 24-72hr above 0. Variations between world regulations showed that the FDA, EMA, and CDSCO enjoyed different regulations or ways, which involved the Preclinical, clinical and POIS, affected preclinical and commercialization a lot. Inter-professional programs with nanoscience and pharmacology or regulatory affairs were also shown by education measurement specialized field to be more beneficial to workforce preparation, albeit with more complementary application. The global size of nanomedicines market, in 2024, was reported to be USD 150 billion and is projected to grow by a CAGR of 12.5% during the next decade on the basis of patent-protected technologies and industry-academic collaborations. These are revealed through the results of current review that show that the use of the drug delivery systems-based nanotechnology is mainly instigated by co-ordinated approaches in sounds in technical, legal, educational and business domains. The results are significant to researchers, policymakers, educators and industry users so that nanomedicine can be used in modern healthcare efficiently, optimally and fairly..